Use of Hybrid Data-Dependent and -Independent Acquisition Spectral Libraries Empowers Dual-Proteome Profiling

In the context of bacterial infections, it’s crucial that physiological responses could be studied in an built-in method, which means a simultaneous evaluation of each the host and the pathogen responses. To enhance the sensitivity of detection, data-independent acquisition (DIA)-based proteomics was discovered to outperform data-dependent acquisition (DDA) workflows in figuring out and quantifying low-abundant proteins.

Here, by making use of consultant bacterial pathogen/host proteome samples, we report an optimized hybrid library technology workflow for DIA mass spectrometry counting on the use of data-dependent and in silico-predicted spectral libraries. When in comparison with looking out DDA experiment-specific libraries solely, the use of hybrid libraries considerably improved peptide detection to an extent suggesting that infection-relevant host-pathogen situations may very well be profiled in ample depth with out the necessity of a priori bacterial pathogen enrichment when finding out the bacterial proteome.

Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer by way of a Multi-omics Integrative Analysis

In this work, we suggest iProFun, an integrative evaluation device to display screen for proteogenomic purposeful traits perturbed by DNA copy quantity alterations (CNAs) and DNA methylations. The objective is to characterize purposeful penalties of DNA copy quantity and methylation alterations in tumors and to facilitate screening for most cancers drivers contributing to tumor initiation and development. Specifically, we take into account three purposeful molecular quantitative traits: mRNA expression ranges, international protein abundances, and phosphoprotein abundances.

We goal to determine these genes whose CNAs and/or DNA methylations have cis-associations with both some or all three varieties of molecular traits. Compared with analyzing every molecular trait individually, the joint modeling of multi-omics knowledge enjoys a number of advantages: iProFun skilled enhanced energy for detecting vital cis-associations shared throughout completely different omics knowledge varieties, and it additionally achieved higher accuracy in inferring cis-associations distinctive to sure sort(s) of molecular trait(s). For instance, distinctive associations of CNAs/methylations to international/phospho protein abundances might indicate posttranslational laws.

We utilized iProFun to ovarian high-grade serous carcinoma tumor knowledge from The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium and recognized CNAs and methylations of 500 and 121 genes, respectively, affecting the cis-functional molecular quantitative traits of the corresponding genes. We noticed substantial energy acquire by way of the joint evaluation of iProFun. For instance, iProFun recognized 117 genes whose CNAs have been related to phosphoprotein abundances by leveraging mRNA expression ranges and international protein abundances. By comparability, analyses primarily based on phosphoprotein knowledge alone recognized none.

A community evaluation of these 117 genes revealed the recognized oncogene AKT1 as a key hub node interacting with many of the remainder. In addition, iProFun recognized one gene, BIN2, whose DNA methylation has cis-associations with its mRNA expression, international protein, and phosphoprotein abundances. These and different genes recognized by iProFun might function potential drug targets for ovarian most cancers. The want for diagnostic biomarkers of cognitive decline is especially vital amongst getting older adults with Down syndrome (DS). Growing empirical assist has recognized the utility of plasma derived biomarkers amongst neurotypical adults with gentle cognitive impairment (MCI) and Alzheimer’s illness (AD); nevertheless, the appliance of such biomarkers has been restricted among the many DS inhabitants.

Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors

The current accomplishment of complete proteogenomic evaluation of high-grade serous ovarian carcinoma (HGSOC) tissues reveals most cancers related molecular alterations weren’t restricted to variations amongst DNA, and mRNA/protein expression, however are a end result of advanced reprogramming of signaling pathways/networks mediated by the protein and post-translational modification (PTM) interactomes. A scientific, multiplexed strategy interrogating enzyme-substrate relationships within the context of PTMs is key in understanding the dynamics of these pathways, regulation of mobile processes, and their roles in illness processes.

Here, as half of Clinical Proteomic Tumor Analysis Consortium (CPTAC) mission, we established a multiplexed PTM assay (tyrosine phosphorylation, and lysine acetylation, ubiquitylation and SUMOylation) methodology to determine protein probes’ PTMs on the human proteome array. Further, we centered on the tyrosine phosphorylation and recognized 19 kinases are doubtlessly chargeable for the dysregulated signaling pathways noticed in HGSOC. Additionally, elevated kinase exercise was noticed when 14 ovarian most cancers cell strains or tumor tissues have been subjected to check the autophosphorylation standing of PTK2 (pY397) and PTK2B (pY402) as a proxy for kinase exercise.

Taken collectively, this report demonstrates that PTM signatures primarily based on lysate reactions on human proteome array is a strong, unbiased strategy to determine dysregulated PTM pathways in tumors. During the final century, most cancers biology has been arguably one of essentially the most investigated analysis fields. To acquire deeper perception into most cancers mechanisms, scientists have been making an attempt to combine multi omics knowledge in most cancers analysis. Cancer genomics, transcriptomics, metabolomics, proteomics, and metagenomics are the principle multi omics methods used at present within the prognosis, prognosis, remedy, and biomarker discovery in most cancers.

JAG-1, scrambled
MBS5789393-INQUIRE	MyBiosource	INQUIRE	Ask for price

JAG-1, scrambled
TP1686-10mg	TargetMol Chemicals	10mg	Ask for price
Description: JAG-1, scrambled

JAG-1, scrambled
TP1686-1g	TargetMol Chemicals	1g	Ask for price
Description: JAG-1, scrambled

JAG-1, scrambled
TP1686-1mg	TargetMol Chemicals	1mg	Ask for price
Description: JAG-1, scrambled

JAG-1, scrambled
TP1686-50mg	TargetMol Chemicals	50mg	Ask for price
Description: JAG-1, scrambled

JAG-1, scrambled
TP1686-5mg	TargetMol Chemicals	5mg	Ask for price
Description: JAG-1, scrambled

Human NEP1-40 of Nogo-66 peptide, Scrambled peptide control for NEP140, >95% pure
NEP140-115	Alpha Diagnostics	100 ug	EUR 343.2

Human NEP1-40 of Nogo-66 peptide Scrambled peptide control for NEP140 >95% pure
NEP140-115-1000	Alpha Diagnostics	1000 ug	EUR 927.6

Scrambled shRNA Control Lentivirus
LSV-0024-1S	LipExoGen	2x10^6	EUR 395
Description: vsv-g

Scrambled shRNA Control Lentivirus
LSV-0024-2S	LipExoGen	2x10^6	EUR 395
Description: vsv-g

Scrambled shRNA Control Lentivirus
LSV-0024-3S	LipExoGen	2x10^6	EUR 395
Description: vsv-g

Scrambled shRNA Control Lentivirus
LSV-0024-4S	LipExoGen	2x10^6	EUR 395
Description: vsv-g

Scrambled shRNA Control Lentivirus
LSV-0024-5S	LipExoGen	2x10^6	EUR 395
Description: vsv-g

Scrambled shRNA Control Lentivirus
LSV-0024-6S	LipExoGen	2x10^6	EUR 395
Description: vsv-g

Scrambled shRNA Control Lentivirus
LSV-0024-7S	LipExoGen	2.5x10^6	EUR 395
Description: vsv-g

Scrambled shRNA Control Lentivirus
LSV-0024-8S	LipExoGen	2.5x10^6	EUR 395
Description: vsv-g

LL-37 scrambled peptide
HY-P1513	MedChemExpress	1mg	EUR 418.8

LL-37 scrambled peptide
MBS5763833-1mg	MyBiosource	1mg	EUR 260

LL-37 scrambled peptide
MBS5763833-5mg	MyBiosource	5mg	EUR 760

LL-37 scrambled peptide
MBS5763833-5x5mg	MyBiosource	5x5mg	EUR 3265

LL-37 scrambled peptide
TP1825-10mg	TargetMol Chemicals	10mg	Ask for price
Description: LL-37 scrambled peptide

LL-37 scrambled peptide
TP1825-1g	TargetMol Chemicals	1g	Ask for price
Description: LL-37 scrambled peptide

LL-37 scrambled peptide
TP1825-1mg	TargetMol Chemicals	1mg	Ask for price
Description: LL-37 scrambled peptide

LL-37 scrambled peptide
TP1825-50mg	TargetMol Chemicals	50mg	Ask for price
Description: LL-37 scrambled peptide

LL-37 scrambled peptide
TP1825-5mg	TargetMol Chemicals	5mg	Ask for price
Description: LL-37 scrambled peptide

Scrambled TRAP Fragment Peptide
20-abx265858	Abbexa	Ask for price Ask for price Ask for price	5 mg 10 mg 25 mg

Scrambled TRAP Fragment Peptide
abx265858-200tests	Abbexa	200 tests	EUR 225

Scrambled TRAP Fragment Peptide
abx265858-500tests	Abbexa	500 tests	EUR 312.5

Scrambled-peptide Knockdown Control Cell Line Expressing Dendra2
T6521	ABM	1x10^6 cells / 1.0 ml	Ask for price

sgp91 ds-tat Peptide 2, scrambled
MBS5789300-INQUIRE	MyBiosource	INQUIRE	Ask for price

sgp91 ds-tat Peptide 2, scrambled
TP1585-10mg	TargetMol Chemicals	10mg	Ask for price
Description: sgp91 ds-tat Peptide 2, scrambled

sgp91 ds-tat Peptide 2, scrambled
TP1585-1g	TargetMol Chemicals	1g	Ask for price
Description: sgp91 ds-tat Peptide 2, scrambled

sgp91 ds-tat Peptide 2, scrambled
TP1585-1mg	TargetMol Chemicals	1mg	Ask for price
Description: sgp91 ds-tat Peptide 2, scrambled

sgp91 ds-tat Peptide 2, scrambled
TP1585-50mg	TargetMol Chemicals	50mg	Ask for price
Description: sgp91 ds-tat Peptide 2, scrambled

sgp91 ds-tat Peptide 2, scrambled
TP1585-5mg	TargetMol Chemicals	5mg	Ask for price
Description: sgp91 ds-tat Peptide 2, scrambled

JAG-1, scrambled TFA (402941-23-5 free base)
MBS5765434-10mg	MyBiosource	10mg	EUR 335

JAG-1, scrambled TFA (402941-23-5 free base)
MBS5765434-25mg	MyBiosource	25mg	EUR 545

JAG-1, scrambled TFA (402941-23-5 free base)
MBS5765434-2mg	MyBiosource	2mg	EUR 210

JAG-1, scrambled TFA (402941-23-5 free base)
MBS5765434-50mg	MyBiosource	50mg	EUR 780

JAG-1, scrambled TFA (402941-23-5 free base)
MBS5765434-5mg	MyBiosource	5mg	EUR 255

JAG-1, scrambled TFA(402941-23-5 free base）
TP1686L-10mg	TargetMol Chemicals	10mg	Ask for price
Description: JAG-1, scrambled TFA(402941-23-5 free base）

JAG-1, scrambled TFA(402941-23-5 free base）
TP1686L-1g	TargetMol Chemicals	1g	Ask for price
Description: JAG-1, scrambled TFA(402941-23-5 free base）

JAG-1, scrambled TFA(402941-23-5 free base）
TP1686L-1mg	TargetMol Chemicals	1mg	Ask for price
Description: JAG-1, scrambled TFA(402941-23-5 free base）

JAG-1, scrambled TFA(402941-23-5 free base）
TP1686L-50mg	TargetMol Chemicals	50mg	Ask for price
Description: JAG-1, scrambled TFA(402941-23-5 free base）

JAG-1, scrambled TFA(402941-23-5 free base）
TP1686L-5mg	TargetMol Chemicals	5mg	Ask for price
Description: JAG-1, scrambled TFA(402941-23-5 free base）

3-D Life Scrambled RGD Peptide
09-P-003	Cellendes	1 µmol	EUR 121

3-D Life Scrambled RGD Peptide
P11-3	Cellendes	3x 1 µmol	EUR 330

PGMtide Control Peptide
040-70	PHOENIX PEPTIDE	100 μg	EUR 316.44

Scrambled shRNA Control THP-1 Cell Line (With GFP) -Polyclone
T9790	ABM	1x10^6 cells / 1.0 ml	Ask for price

L201 pLVPTH2- tTR- KRAB- Cerulean- scrambled- shRNA- Control
PVT11122	Lifescience Market	2 ug	EUR 361.2

Scrambled Cathelicidin antimicrobial peptide 18
SB010	Smartox Biotechnology	1	EUR 134.41
Description: Scrambled LL-37 has the same peptide sequence as LL-37 but loses helixforming property.Scrambled LL-37 can be used as a negative control of LL-37 studies.

JAG-1 Protein Active Peptide Fragment
080-11	PHOENIX PEPTIDE	100 μg	EUR 129.6

PGMtide Control Peptide - FAM Labeled
FG-040-70A	PHOENIX PEPTIDE	5 nmol	EUR 537.84

PGMtide Control Peptide - Cy3 Labeled
FC3-040-70	PHOENIX PEPTIDE	1 nmol	EUR 925.56

PGMtide Control Peptide - Biotin Labeled
B-040-70	PHOENIX PEPTIDE	20 μg	EUR 537.84

PGMtide Control Peptide - Rhodamine Labeled
FR-040-70	PHOENIX PEPTIDE	5 nmol	EUR 604.8

Human, mouse, rat connexin 43 and 37 scrambled peptide (GAP27 domain)
Cx2704-PS-1	Alpha Diagnostics	1 mg	EUR 315.6

Human, mouse, rat connexin 43 and 37 scrambled peptide (GAP27 domain)
Cx2704-PS-5	Alpha Diagnostics	5 mg	EUR 927.6

Human, mouse, rat connexin 37/40 hemi-channel Scrambled peptide (GAP26 domain)
Cx2602-PS-1	Alpha Diagnostics	1 mg	EUR 343.2

Human, mouse, rat connexin 37/40 hemi-channel Scrambled peptide (GAP26 domain)
Cx2602-PS-5	Alpha Diagnostics	5 mg	EUR 927.6

ZIP (SCRAMBLED)
A8830-1	ApexBio	1 mg	EUR 74.4
Description: TGF-β / Smad Signaling|PKC

PADRE scrambled
SB084	Smartox Biotechnology	1	EUR 81.81
Description: SB-peptide offers the scrambled version of PADRE peptide. AAATLWKAAKFVA can be used as a negative control of PADRE peptide studies.SB-peptide offers also PADRE peptide (see section PADRE peptide).PADRE peptide: Pan HLA DR-binding epitope is a universal peptide that activates antigen specific-CD4+ T cells which can be used as an agonist adjuvant in immunotherapeutic vaccine development. Pan HLA DR-binding epitope has been proposed as a carrier epitope suitable for use in the development of synthetic and recombinant vaccines. It has been demonstrated that PADRE may be an universal approach to control tumor cells. Moreover, PADRE is also used in research about an immunosense approach to develop a base for development of vaccines against toxoplasmosis to protect person with HLA-A*03 type. Pan HLA DR-binding epitope can be also used as tool to study the autoreactive T cell response.

Scrambled 10Panx
A2701-1	ApexBio	1 mg	EUR 40
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction

Scrambled 10Panx
A2701-10	ApexBio	10 mg	EUR 144
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction

Scrambled 10Panx
A2701-25	ApexBio	25 mg	EUR 320
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction

Scrambled 10Panx
A2701-5	ApexBio	5 mg	EUR 80
Description: Neuroscience|Gap Junction#Membrane Transporter/Ion Channel|Pannexin-1#Other Signal Transduction

Scrambled 10Panx
MBS3840702-10mg	MyBiosource	10mg	EUR 235

Scrambled 10Panx
MBS3840702-25mg	MyBiosource	25mg	EUR 430

Scrambled 10Panx
MBS3840702-5mg	MyBiosource	5mg	EUR 165

Scrambled 10Panx
MBS3840702-5x25mg	MyBiosource	5x25mg	EUR 1920

LL-37 (scrambled)
4099707.05	Bachem	0.5 mg	EUR 195.51

LL-37 (scrambled)
4099707.1	Bachem	1 mg	EUR 317.94

LL-37 (scrambled)
H-7886.0500	Bachem	0.5mg	EUR 339.6
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net

LL-37 (scrambled)
H-7886.1000	Bachem	1.0mg	EUR 529.2
Description: Sum Formula: C205H340N60O53; CAS# [1354065-56-7] net

ZIP (SCRAMBLED) Acetate
MBS5773250-1mg	MyBiosource	1mg	EUR 190

ZIP (SCRAMBLED) Acetate
MBS5773250-2mg	MyBiosource	2mg	EUR 235

ZIP (SCRAMBLED) Acetate
MBS5773250-5mg	MyBiosource	5(mg	EUR 300

ZIP (SCRAMBLED) Acetate
T22175L-10mg	TargetMol Chemicals	10mg	Ask for price
Description: ZIP (SCRAMBLED) Acetate

ZIP (SCRAMBLED) Acetate
T22175L-1g	TargetMol Chemicals	1g	Ask for price
Description: ZIP (SCRAMBLED) Acetate

ZIP (SCRAMBLED) Acetate
T22175L-1mg	TargetMol Chemicals	1mg	Ask for price
Description: ZIP (SCRAMBLED) Acetate

ZIP (SCRAMBLED) Acetate
T22175L-50mg	TargetMol Chemicals	50mg	Ask for price
Description: ZIP (SCRAMBLED) Acetate

ZIP (SCRAMBLED) Acetate
T22175L-5mg	TargetMol Chemicals	5mg	Ask for price
Description: ZIP (SCRAMBLED) Acetate

OVA 257-264 scrambled
SB073	Smartox Biotechnology	1	EUR 81.81
Description: SB-peptide offers the scrambled version of OVA 257-264. FILKSINE can be used as a negative control of OVA 257-264 studies.SB-peptide offers also OVA 257-264 (see section OVA 257-264).Ovalbumin protein:OVA 257-264 (H-2Kb) is an epitope of interest of the egg white albumen, ovalbumin. Ovalbumin is a glycoprotein that is sufficiently large and complex to be mildly immunogenic. Indeed, it has been demonstrated that Ovalbumin contains B-cell epitopes which are recognized by specific IgE antibodies and CD4 T cell epitopes restricted by the MHC I-Ad molecule in mice and by HLA-D molecule in human.Applications of OVA 257-264:OVA 257-264 is used to stimulate T cells in PBMCs and to quantify peptide epitope specificity and IFN-γ releasing effector cells by ELISPOT assay. OVA 257-264 is also used to test new adjuvant in immunotherapeutic vaccine development. OVA 257-264 can form a stable hydrogel and stimulate a immune response. This reaction seems to be linked with OVA 257-264 property to self-assemble into a hydrogel. Sequence:C45H74N10013

Scrambled TRAP Fragment
5-01910	CHI Scientific	4 x 5mg	EUR 155.61
Description: Phe-Ser-Leu-Leu-Arg-Asn-NH2

Scrambled TRAP Fragment
MBS5799340-5mg	MyBiosource	5(mg	EUR 915

Scrambled TRAP Fragment
MBS5799340-5x5mg	MyBiosource	5x5(mg	EUR 3970

Scrambled TRAP Fragment
MBS8247030-10mg	MyBiosource	10mg	EUR 560

Scrambled TRAP Fragment
MBS8247030-1mg	MyBiosource	1mg	EUR 225

Scrambled TRAP Fragment
MBS8247030-5mg	MyBiosource	5mg	EUR 400

Scrambled TRAP Fragment
MBS8247030-5x10mg	MyBiosource	5x10mg	EUR 2435

Scrambled TRAP Fragment
T38743-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Scrambled TRAP Fragment

Scrambled TRAP Fragment
T38743-1g	TargetMol Chemicals	1g	Ask for price
Description: Scrambled TRAP Fragment

Scrambled TRAP Fragment
T38743-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Scrambled TRAP Fragment

Scrambled TRAP Fragment
T38743-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Scrambled TRAP Fragment

Scrambled TRAP Fragment
T38743-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Scrambled TRAP Fragment

Neuropeptide Y (scrambled)
B7530-1	ApexBio	1 mg	EUR 486
Description: Scrambled Neuropeptide Y (scNPY) was similarly synthesized and contains the same amino acids as NPY, but scNPY is in a random sequence, it was used as a control in the research in NPY [1]. The sequence of scNPY is SKPQRDANREPTRYAIYDYSNPDIELHYLRPAYALG-NH2 [2].

Neuropeptide Y (scrambled)
MBS5764161-1mg	MyBiosource	1mg	EUR 625

Neuropeptide Y (scrambled)
MBS5764161-5x1mg	MyBiosource	5x1mg	EUR 2655

Neuropeptide Y (scrambled)
TP2194-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Neuropeptide Y (scrambled)

Neuropeptide Y (scrambled)
TP2194-1g	TargetMol Chemicals	1g	Ask for price
Description: Neuropeptide Y (scrambled)

Neuropeptide Y (scrambled)
TP2194-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Neuropeptide Y (scrambled)

Neuropeptide Y (scrambled)
TP2194-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Neuropeptide Y (scrambled)

Neuropeptide Y (scrambled)
TP2194-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Neuropeptide Y (scrambled)

Mouse Lipin-1 Control/blocking peptide control/blocking peptide #1
LPN11-P	Alpha Diagnostics	100 ug	EUR 196.8

Amyloid β-Protein (1-42) (scrambled)
4064853.05	Bachem	0.5 mg	EUR 317.94

Amyloid β-Protein (1-42) (scrambled)
4064853.1	Bachem	1 mg	EUR 432.6

Amyloid b-Protein (1-42) (scrambled)
H-7406.0500	Bachem	0.5mg	EUR 529.2
Description: Sum Formula: C203H311N55O60S; CAS# [1678415-52-5] net

Amyloid b-Protein (1-42) (scrambled)
H-7406.1000	Bachem	1.0mg	EUR 706.8
Description: Sum Formula: C203H311N55O60S; CAS# [1678415-52-5] net

Amyloid b-Protein (1-40) (scrambled)
H-7408.0500	Bachem	0.5mg	EUR 402
Description: Sum Formula: C194H295N53O58S; CAS# [1678415-68-3] net

Amyloid b-Protein (1-40) (scrambled)
H-7408.1000	Bachem	1.0mg	EUR 727.2
Description: Sum Formula: C194H295N53O58S; CAS# [1678415-68-3] net

MAGE-A p248V9 scrambled
SB080	Smartox Biotechnology	1	EUR 93.5
Description: SB-peptide offers the scrambled version of MAGE-A p248V9. RQYVELPYV can be used as a negative control of MAGE-A p248V9 studies.SB-peptide offers also MAGE-A p248V9 (see section MAGE-A p248V9)).MAGE-A protein:MAGE-A p248V9, also kwon as multi-MAGE-A (YLEYRQVPV) is an epitope of Melanoma Antigen Gene expressed by tumors of different histological types and is a Cancer/Testis Antigens (CTA). Type of MAGE-A expressed in tumors cells varies according to the type of tumor. Targeting epitopes shared by all MAGE-A antigens would be interest in immunotherapy against a broad spectrum of cancers. Applications of MAGE-A p248V9 (multi-MAGE-A) :MAGE-A p248V9 is very useful because it could generate an HLA-A*02:01-restricted CTL response and shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10 and -A12. MAGE-A p248V9 is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay.Sequence : RQYVELPYV

Human MDM2 siRNA (Scrambled)
abx941274-150g	Abbexa	150 µg	EUR 450

Human MDM2 siRNA (Scrambled)
abx941274-300g	Abbexa	300 µg	EUR 612.5

Mouse Lipin-2 Control/blocking peptide control/blocking peptide #1
LPN21-P	Alpha Diagnostics	100 ug	EUR 196.8

Mouse Lipin-3 Control/blocking peptide control/blocking peptide #1
LPN31-P	Alpha Diagnostics	100 ug	EUR 196.8

PAR-2 (1-6) amide (human) (scrambled)
H-6428.0025	Bachem	25.0mg	EUR 385.2
Description: Sum Formula: C28H54N8O7; CAS# [1348395-60-7] net

PAR-2 (1-6) amide (human) (scrambled)
H-6428.0100	Bachem	100.0mg	EUR 1082.4
Description: Sum Formula: C28H54N8O7; CAS# [1348395-60-7] net

Melan-A (26-35) scrambled
SB081	Smartox Biotechnology	1	EUR 64.28
Description: SB-peptide offers the scrambled version of Melan-A/MART-1 (26-35). AIEIAGGLTV can be used as a negative control of Melan-A/MART-1 (26-35) studies.SB-peptide offers also Melan-A/MART-1 (26-35) (see section Melan-A/MART-1 (26-35)).Native Melan-A (26-35) decapepetide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas1.The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide1. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity1.It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide. Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide1. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min)1.Sequence : AIEIAGGLTV

MAGE-A2 (157-166) scrambled
SB082	Smartox Biotechnology	1	EUR 93.5
Description: SB-peptide offers the scrambled version of MAGE-A2 (157-166). VLVYFQEIGL can be used as a negative control of MAGE-A2 (157-166) studies.SB-peptide offers also MAGE-A2 (157-166) (see section MAGE-A2 (157-166)).MAGE-A2 protein: MAGE-A2 (157-166) is an epitope of Melanoma Antigen Gene A2 and is one of the most Cancer-Testis Antigens (CTA) overexpressed in tumors of different histological types, such as prostate cancer. Type of MAGE-A expressed in tumors cells varies according to the type of tumor. The expression of MAGE-A2 causes the proliferation of prostate cancer cells and decreases the chemosensitivity. Applications of MAGE-A2 (157-166):MAGE-A2 (157-166) is used to stimulate specific immune response, cytotoxic T cell response and to analyze the cytokine production in PBMCs by ELISPOT assay. In transgenic mouse, it has been demonstrated that MAGE-A2 (157-166) was capable of eliciting a CTL response presented by HLA-A*02:01 molecules. MAGE-A2 (157-166) has been reported to elicit CTL that could lyse tumor cell expressing both HLA-A*02:01 and MAGE-A2 by stimulation of peripheral blood mononuclear cells (PBMCs) with MAGE-A2 (157-166).Sequence : VLVYFQEIGL

MAGE-A1 (278-286) scrambled
SB083	Smartox Biotechnology	1	EUR 93.5
Description: SB-peptide offers the scrambled version of MAGE-A1 (278-286). ELIVKVYKV can be used as a negative control of MAGE-A1 (278-286) studies.SB-peptide offers also MAGE-A1 (278-286) (see section MAGE-A1 (278-286)).MAGE-A1 protein:MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells. Applications of MAGE-A1 (278-286): MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.Sequence : ELIVKVYKV

Human EGFRviii siRNA (Scrambled)
abx941279-150g	Abbexa	150 µg	EUR 450

Human EGFRviii siRNA (Scrambled)
abx941279-300g	Abbexa	300 µg	EUR 612.5

5-FAM-LL-37 (scrambled)
4099708.05	Bachem	0.5 mg	EUR 335.9

5-FAM-LL-37 (scrambled)
4099708.1	Bachem	1 mg	EUR 577.5

5-FAM-LL-37 (scrambled)
H-7888.0500	Bachem	0.5mg	EUR 559.2
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net

5-FAM-LL-37 (scrambled)
H-7888.1000	Bachem	1.0mg	EUR 931.2
Description: Sum Formula: C226H350N60O59; CAS# [2022972-73-0] net

Scrambled sgRNA CRISPR Lentivector
K018	ABM	1.0 ug	EUR 184.8

Amyloid beta-Protein (Human, 1-40) (Scrambled)
MBS407587-01mg	MyBiosource	0.1mg	EUR 215

Amyloid beta-Protein (Human, 1-40) (Scrambled)
MBS407587-5x01mg	MyBiosource	5x0.1mg	EUR 915

Amyloid beta-Protein (Human, 1-42) (Scrambled)
MBS407588-01mg	MyBiosource	0.1mg	EUR 320

Amyloid beta-Protein (Human, 1-42) (Scrambled)
MBS407588-5x01mg	MyBiosource	5x0.1mg	EUR 1385

5-FAM-Amyloid β-Protein (1-42) (scrambled)
4099694.01	Bachem	0.1 mg	EUR 99.96

5-FAM-Amyloid β-Protein (1-42) (scrambled)
4099694.05	Bachem	0.5 mg	EUR 359.52

Teplow's Amyloid β-Protein (1-40) (scrambled II)
4104167.01	Bachem	0.1 mg	EUR 86.52

Teplow's Amyloid β-Protein (1-40) (scrambled II)
4104167.05	Bachem	0.5 mg	EUR 299.99

Teplow's Amyloid β-Protein (1-42) (scrambled II)
4104168.05	Bachem	0.5 mg	EUR 299.99

Teplow's Amyloid β-Protein (1-42) (scrambled II)
4104168.1	Bachem	1 mg	EUR 450.56

Teplow's Amyloid b-Protein (1-40) (scrambled II)
H-8278.0100	Bachem	0.1mg	EUR 170.4
Description: Sum Formula: C194H295N53O58S

Teplow's Amyloid b-Protein (1-40) (scrambled II)
H-8278.0500	Bachem	0.5mg	EUR 501.6
Description: Sum Formula: C194H295N53O58S

Teplow's Amyloid b-Protein (1-42) (scrambled II)
H-8282.0500	Bachem	0.5mg	EUR 501.6
Description: Sum Formula: C203H311N55O60S

Teplow's Amyloid b-Protein (1-42) (scrambled II)
H-8282.1000	Bachem	1.0mg	EUR 734.4
Description: Sum Formula: C203H311N55O60S

5-FAM-Amyloid b-Protein (1-42) (scrambled)
H-7836.0100	Bachem	0.1mg	EUR 192
Description: Sum Formula: C224H321N55O66S

5-FAM-Amyloid b-Protein (1-42) (scrambled)
H-7836.0500	Bachem	0.5mg	EUR 594
Description: Sum Formula: C224H321N55O66S

Biotinyl-εAhx-LL-37 (scrambled)
4099709.05	Bachem	0.5 mg	EUR 326.97

In this evaluate, we describe the use of completely different multi omics methods in most cancers analysis within the African continent and focus on the principle challenges dealing with the implementation of these approaches in African international locations comparable to the shortage of coaching packages in bioinformatics generally and omics methods particularly and counsel paths to handle deficiencies. As a method ahead, we advocate for the institution of an “African Cancer Genomics Consortium” to advertise intracontinental collaborative initiatives and improve engagement in analysis actions that tackle indigenous facets for most cancers precision medication.